Sharma, P., Bono, P., Kim, J. W., Spiliopoulou, P., Calvo, E., Pillai, R. N., … Rosenberg, J. (2016). Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. In Journal of Clinical Oncology (Vol. 34, pp. 4501–4501). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.4501

Sharma, Padmanee, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi Narayana Pillai, Patrick Alexander Ott, et al. “Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.” In Journal of Clinical Oncology, 34:4501–4501. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.4501.

Sharma P, Bono P, Kim JW, Spiliopoulou P, Calvo E, Pillai RN, et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 4501–4501.

Sharma, Padmanee, et al. “Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 4501–4501. Crossref, doi:10.1200/jco.2016.34.15_suppl.4501.

Sharma P, Bono P, Kim JW, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, De Braud FG, Morse MA, Le DT, Jaeger D, Chan E, Harbison CT, Lin C-S, Tschaika M, Azrilevich A, Rosenberg J. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 4501–4501.